Risk of Polypharmacy and Its Outcome in Terms of Drug Interaction in an Elderly Population: A Retrospective Cross-Sectional Study

Author:

Alhumaidi Reham M.1,Bamagous Ghazi A.1,Alsanosi Safaa M.1ORCID,Alqashqari Hamsah S.2,Qadhi Rawabi S.3,Alhindi Yosra Z.1ORCID,Ayoub Nahla1ORCID,Falemban Alaa H.1

Affiliation:

1. Department of Pharmacology and Toxicology, Faculty of Medicine, Umm Al-Qura University, Makkah 24382, Saudi Arabia

2. Department of Community Medicine, Faculty of Medicine, Umm Al-Qura University, Makkah 24382, Saudi Arabia

3. Institute of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow G12 8QQ, UK

Abstract

The simultaneous use of multiple drugs—termed ‘polypharmacy’—is often required to manage multiple physiological and biological changes and the interplay between chronic disorders that are expected to increase in association with ageing. However, by increasing the number of medications consumed, the risk of undesirable medication reactions and drug interactions also increases exponentially. Hence, knowledge of the prevalence of polypharmacy and the risk of potentially serious drug–drug interactions (DDIs) in elderly patients should be considered a key topic of interest for public health and health care professionals. Methods: Prescription and demographic data were collected from the electronic files of patients who were aged ≥ 65 years and attended Al-Noor Hospital in Makkah, Saudi Arabia, between 2015 and 2022. The Lexicomp® electronic DDI-checking platform was used to evaluate the patients’ medication regimens for any potential drug interactions. Results: A total of 259 patients were included in the study. The prevalence of polypharmacy among the cohort was 97.2%: 16 (6.2%) had minor polypharmacy, 35 (13.5%) had moderate polypharmacy, and 201 (77.6%) had major polypharmacy. Of the 259 patients who were taking two or more medications simultaneously, 221 (85.3%) had at least one potential DDI (pDDI). The most frequently reported pDDI under category X that should be avoided was the interaction between clopidogrel and esomeprazole and was found in 23 patients (18%). The most frequently reported pDDI under category D that required therapeutic modification was the interaction between enoxaparin and aspirin, which was found in 28 patients (12%). Conclusions: It is often necessary for elderly patients to take several medications simultaneously to manage chronic diseases. Clinicians should distinguish between suitable, appropriate and unsuitable, inappropriate polypharmacy, and this criterion should be closely examined when establishing a therapeutic plan.

Publisher

MDPI AG

Subject

General Medicine

Reference23 articles.

1. World Health Organization (2022, April 15). Ageing and Health. Available online: https://www.who.int/news-room/fact-sheets/detail/ageing-and-health.

2. Geriatric Syndromes: Clinical, Research, and Policy Implications of a Core Geriatric Concept;Inouye;J. Am. Geriatr. Soc.,2007

3. An overview of prevalence, determinants and health outcomes of polypharmacy;Khezrian;Ther. Adv. Drug Saf.,2020

4. Over-the-counter medicines: Global perspective and Indian scenario;Kamat;J. Postgrad. Med.,2020

5. Bjerrum, L. (1998). Pharmacoepidemiological Studies of Polypharmacy: Methodological Issues, Population Estimates, and Influence of Practice Patterns, Odense University.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3